Inhibrx Inc (INBX) is a clinical-stage biotechnology company that develops a diverse portfolio of novel biologic therapeutic candidates. The company's proprietary platform technology, called InhibiX, enables the discovery and development of therapeutics that target proteins which are difficult to drug using traditional approaches. Inhibrx is focused on developing treatments for oncology, metabolic diseases, and rare genetic disorders.
The company's lead product candidate is INBRX-109, which is currently in Phase 1b/2 clinical trials for the treatment of patients with solid tumors. The drug is designed to target T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), which is overexpressed in several types of cancer and contributes to the suppression of the immune system.
In addition to INBRX-109, Inhibrx has several other product candidates in its pipeline, including INBRX-106, which is being developed as a potential treatment for autoimmune diseases, and INBRX-101, which is being developed for the treatment of alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause lung and liver disease.
Overall, Inhibrx is focused on developing innovative treatments that address significant unmet medical needs, particularly in areas where current therapies are limited or ineffective.
|
